Skip to main content

Table 2 Comparison of clinical characteristics according to the BTLN2 genotype (G/G vs. A/A plus G/A)

From: Familial vs. sporadic sarcoidosis: BTNL2 polymorphisms, clinical presentations, and outcomes in a French cohort

Data

Number

BTNL2

Univariate model raw p value *,**

A/A

G/A

G/G

Epidemiological data

    

0.59

 Ethnicity

292

    

  European

226

103 (75.7%)

104 (80%)

19 (73.1%)

 

  Caribbean or Sub-Saharan African

66

33 (24.3%)

26 (20%)

7 (26.9%)

 

Clinical data at diagnosis

 Disease onset

389

   

0.91

  Asymptomatic

130

60 (34.29%)

59 (33.15%)

11 (30.56%)

 

  Symptomatic

259

115 (65.71%)

119 (66.85%)

25 (69.44%)

 

 Löfgren syndrome

368

   

0.042 [0.42]

  Yes

58

25 (14.71%)

32 (19.39%)

1 (3.03%)

 

  No

310

145 (85.29%)

133 (80.61%)

32 (96.97%)

 

 Number of organs involved

397

   

0.074

  1

152

70 (38.46%)

73 (41.01%)

9 (24.32%)

 

  2

115

55 (30.22%)

49 (27.53%)

11 (29.73%)

 

  3

66

29 (15.93%)

33 (18.54%)

4 (10.81%)

 

   ≥ 4

64

28 (15.39%)

23 (12.92%)

13 (35.14%)

 

 Organs involved

397

   

0.082

  Lungs only

143

68 (37.36%)

67 (37.64%)

8 (21.62%)

 

  Lungs and Eyes

52

23 (12.64%)

20 (11.24%)

9 (24.33%)

 

  Lungs and Skin

20

11 (6.04%)

8 (4.49%)

1 (2.7%)

 

  Other sites

182

80 (43.96%)

83 (46.63%)

19 (51.35%)

 

 X-ray staging

432

   

0.26

  0

57

25 (12.5%)

26 (13.47%)

6 (15.38%)

 

  1

158

77 (38.5%)

65 (33.68%)

16 (41.03%)

 

  2

149

67 (33.5%)

68 (35.23%)

14 (35.9%)

 

  3

47

24 (12%)

22 (11.4%)

1 (2.56%)

 

  4

21

7 (3.5%)

12 (6.22%)

2 (5.13%)

 

PFT at first visit

 TLC (%)

    

0.098

   < 80%

47

23 (24.47%)

22 (23.91%)

2 (9.52%)

 

   ≥ 80%

160

71 (75.53%)

70 (76.09%)

19 (90.48%)

 

Pattern of disease course

 SCAC

398

   

0.83

  1- symptomatic - no treatment

46

21 (11.6%)

22 (12.1%)

3 (8.3%)

 

  2- symptomatic - treatment ≤ 12 mo.

47

19 (10.5%)

22 (12.1%)

6 (16.7%)

 

  3- symptomatic - treatment > 12 mo.

166

75 (41.4%)

74 (40.9%)

17 (47.2%)

 

  4- asymptomatic - no treatment

48

19 (10.5%)

26 (14.4%)

3 (8.3%)

 

  5- asymptomatic - treatment ≤ 12 mo.

14

6 (3.3%)

7 (3.9%)

1 (2.8%)

 

  6- asymptomatic - treatment > 12 mo.

77

41 (22.7%)

30 (16.6%)

6 (16.7%)

 

 Classification of outcome

137

   

0.015 [0.14]***

  1- recovery within 3 years

72

29 (52.73%)

36 (52.17%)

7 (53.85%)

 

  2- recovery between 3 and 5 years

32

9 (16.36%)

17 (24.64%)

6 (46.15%)

 

  3- no recovery at 5 years

29

15 (27.27%)

14 (20.29%)

0 (0%)

 

  4- death

4

2 (3.64%)

2 (2.9%)

0 (0%)

 
  1. *Significant raw p-values are followed by corrected p-values (Bonferroni correction) in brackets
  2. **Small “Death” category excluded
  3. ***G/G vs. G/A + A/A